National Institute for Health and Clinical Excellence (NICE)
NICE, PHE and SACN publish rapid COVID-19 guidance on vitamin D
NICE, PHE and SACN yesterday published rapid guidance on vitamin D for COVID-19
In collaboration with Public Health England (PHE), and the Scientific Advisory Committee on Nutrition (SACN), NICE conducted a rapid evidence review evaluating evidence from recent studies on vitamin D in relation to COVID-19.
The expert panel supported current government advice for everyone to take the supplement throughout the autumn and winter, however the panel concluded that there is currently not enough evidence to support taking vitamin D solely to prevent or treat COVID-19.
The data reviewed by the panel includes the best available scientific evidence published so far, including both observational studies and randomised controlled trials. However, it was not possible to determine a direct relationship between vitamin D and COVID-19 based on the available evidence.
Due to the lack of reliable evidence on the effects of the supplement on COVID-19, our guidance recommends that more research be conducted on the subject, stressing the use of high-quality randomised controlled trials in future studies.
Dr Paul Chrisp, director of the Centre for Guidelines at NICE, said: “While there is insufficient evidence to recommend vitamin D for the prevention or treatment of COVID-19 at this time, we encourage people to follow government advice on taking the supplement throughout the autumn and winter period.
“As research continues on the impact of vitamin D on COVID-19, we are continuing to monitor evidence as it is published and will review and update the guidance if necessary.”
The new guidance states that people should continue to follow the current government advice on daily vitamin D supplementation to maintain bone and muscle health during the COVID-19 pandemic.
Professor Ian Young, Chair of the Scientific Advisory Committee on Nutrition, which advises PHE and other UK government organisations on nutrition and related health matters, said: “SACN has worked closely with NICE and PHE to consider the available evidence from recent studies on vitamin D in relation to COVID-19. This evidence review confirms that currently there is not enough available evidence to determine that there is a causal relationship between vitamin D and COVID-19.”
It is recommended that everyone should take a daily 10 microgram (400 international units) vitamin D supplement from October to early March. This dose is safe and effective at maintaining healthy vitamin D blood levels.
Vitamin D is required for the maintenance of healthy bone and muscle. Although sunlight exposure is the major source of vitamin D for most people during summer months, it can also be obtained from the diet or supplements.
Many people have been indoors more than usual this spring and summer, which means we might not have been making enough vitamin D from sunlight. So, it’s even more important this year to take a vitamin D supplement as we go into the winter months.
Some people are more at risk of not having enough vitamin D even in spring and summer, including those with dark skin (such as those with African, African-Caribbean or south Asian backgrounds), those who are not outdoors often, those in care homes, and those who cover up most of the skin when outdoors. We advise these people to take a vitamin D supplement all year round. Clinically vulnerable groups will also be eligible for free vitamin D supplements throughout the winter period, starting in January.
Dr Alison Tedstone, chief nutritionist at Public Health England, said: “Vitamin D is important for our bone and muscle health.
“We advise that everyone, particularly the elderly, those who don’t get outside and those with dark skin, takes a vitamin D supplement containing 10 micrograms (400IU) every day.
“This year, the advice is more important than ever with more people spending more time inside.”
Latest News from
National Institute for Health and Clinical Excellence (NICE)
Thousands of breast cancer patients to have routine access to NICE-approved drug combination01/03/2021 15:28:15
Another potentially life-extending drug combination for some people with advanced breast cancer will now be available for routine use after draft guidance from NICE recommended ribociclib (also called Kisqali and made by Novartis) is taken out of the Cancer Drugs Fund (CDF).
Hundreds of people set to benefit as NICE recommends selective internal radiation therapy for treating advanced liver cancer26/02/2021 16:15:00
Hundreds of people with advanced liver cancer (also called hepatocellular carcinoma or HCC) are set to benefit after NICE today (26 February 2021) published final draft guidance recommending a cancer treatment called selective internal radiation therapy (SIRT) as an option for treating the condition.
NHS patients to benefit from first full access deal in Europe for new CAR-T therapy recommended by NICE25/02/2021 15:20:00
NICE has agreed a managed access agreement, via the Cancer Drugs Fund with manufacturer Kite, so more data can be collected while patients can access the treatment.
NICE draft guidance recommends sapropterin for children with rare inherited metabolic condition phenylketonuria25/02/2021 14:15:00
NICE has today (25 February 2021) issued draft guidance for public consultation which recommends sapropterin (also called Kuvan and made by BioMarin) for treating phenylketonuria (PKU) in children aged up to 18.
A new instrument for consideration of a broader range of benefits for people, their families and carers18/02/2021 14:15:00
Blog posted by: Bhash Naidoo Senior Technical Adviser – Health Economics at NICE, 17 February 2021.
Skin cancer drug recommended for routine NHS use15/02/2021 09:15:00
An appeal period has now opened until 26 February 2021.
NICE recommends treatment options for severe pregnancy sickness in new draft guidance11/02/2021 15:15:00
Nausea and vomiting, often referred to as morning sickness, is common in pregnancy. Close to 80% of pregnant women experience these symptoms, with most conditions improving or stopping completely by around 16 to 20 weeks
NICE’s processes of technology evaluation - presenting a case for change04/02/2021 15:20:00
NICE has today (4 February 2021) launched a public consultation on proposals for changes to the processes it uses to develop its guidance on medicines, medical devices, diagnostics and digital health technologies